Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease

IDrugs

Volumn 12, Issue 10, 2009, Pages 648-655

  Riley, R F ^a   Corson, M A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DARAPLADIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOENZYME; LIPID; PLACEBO; TYRISA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTERY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CELL COUNT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENZYME INHIBITION; HEART DEATH; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIPID METABOLISM; MACROPHAGE; MEGALOBLASTIC ANEMIA; NONHUMAN; PHENOTYPE; PREDICTION; REVIEW; RISK; SIDE EFFECT; STROKE; STRUCTURE ACTIVITY RELATION; SWINE; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; TASTE DISORDER;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADMINISTRATION, ORAL; ANIMALS; ATHEROSCLEROSIS; BENZALDEHYDES; CORONARY ARTERY DISEASE; ENZYME INHIBITORS; HUMANS; OXIMES;

EID: 70349772216     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. 370757 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2. Boyd HF, Flynn ST, Hickey DMB, Ife RJ, Jones M, Leach CA, Macphee CH, Milliner KJ, Rawlings DA, Slingsby BP, Smith SA et al BIOORG MED CHEM LETT 2000 10 4 395-398
2. 400047 Partners. Human Genome Sciences Inc COMPANY WORLD WIDE WEB SITE 2001 February 26
3. 401355 The identification of a potent, water soluble inhibitor of lipoprotein-associated phospholipase A2. Boyd HF, Hammond B, Hickey DMB, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ, Pinto IL, Smith SA, Stansfield IG et al BIOORG MED CHEM LETT 2001 11 5 701-704
4. 416029 1-(Arylpiperazinylamidoalkyl)-pyrimidones: Orally active inhibitors of lipoprotein-associated phospholipase A2. Bloomer JC, Boyd HF, Hickey DMB, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Pinto IL, Rawlings DA, Smith SA, Stansfield IG et al BIOORG MED CHEM LETT 2001 11 14 1925-1929
5. 433987 Potent, orally active inhibitors of lipoprotein-associated phospholipase A2: 1-(Biphenylmethylamidoalkyl)-pyrimidones. Boyd HF, Fell SCM, Hickey DMB, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Pinto IL, Rawlings DA, Smith SA, Stansfield IG et al BIOORG MED CHEM LETT 2002 12 1 51-55
6. 465883 The discovery of SB-435495: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man. Blackie JA, Bloomer JC, Brown MJB, Cheng H-Y, Elliott RL, Hammond B, Hickey MB, Ife RJ, Leach CA, Lewis AA, Macphee CH et al BIOORG MED CHEM LETT 2002 12 18 2603-2606
7. 482131 Design of clinical candidate SB-480848: A new inhibitor of lipoprotein-associated phospholipase A2 with enhanced in vivo profile. Leach CA ACS 2003 225 Abs MEDI 154
8. 483668 The identification of clinical candidate SB-480848: A potent inhibitor of lipoprotein-associated phospholipase A2. Blackie JA, Bloomer JC, Brown MJ, Cheng HY, Hammond B, Hickey DM, Ife RJ, Leach CA, Lewis VA, Macphee CH, Milliner KJ et al BIOORG MED CHEM LETT 2003 13 6 1067-1070
9. 486283 Medicinal chemistry in eastern England - 14th Symposium, Hatfield, UK, 10 April 2003. Norman P IDDB MEETING REPORT 2003 April 10
10. 506655 An integrated pharmacokinetic/pharmacodynamic (PK/PD) model for SB-480848 inhibition of plasma lipoproteinassociated phospholipase A2 (Lp-PLA2) enzyme activity in human. Magee MH, Ilson BE, Shaddinger BC, Hossain M CLIN PHARMACOL THER 2003 73 2 86-87
11. 511941 N-1 substituted pyrimidin-4-ones: Novel, orally active inhibitors of lipoprotein-associated phospholipase A2. Boyd HF, Fell SC, Flynn ST, Hickey DM, Ife RJ, Leach CA, Macphee CH, Milliner KJ, Moores KE, Pinto IL, Porter RA BIOORG MED CHEM LETT 2000 10 22 2557-2561
12. 638027 Product development pipeline, GSK: November 2005 GlaxoSmithKline plc COMPANY WORLD WIDE WEB SITE 2005 November 30
13. 905078 The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent. Mohler ER III, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A J AM COLL CARDIOL 2008 51 17 1632-1641
14. 924845 The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Becker RC, Meade TW, Berger PB, Ezekowitz M, O'Connor CM, Vorchheimer DA, Guyatt GH, Mark DB, Harrington RA CHEST 2008 133 6 Suppl 776S-814S
15. 939931 Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C et al CIRCULATION 2008 118 11 1172-1182
16. 971853 FYI from human genome sciences: GSK initiates darapladib phase 3 development program. Human Genome Sciences Inc; GlaxoSmithKline plc PRESS RELEASE 2008 December 18
17. 997899 Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: The results of a multicenter clinical study. Johnson A, Zalewski A, Janmohamed S, Sawyer J, Rolfe T, Staszkiewicz W, Sabin JA CIRCULATION 2004 110 17
18. 1019558 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ J AM COLL CARDIOL 2004 44 3 720-732
19. -1024536 European cardiovascular disease statistics 2008 edition. Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, Gray A INTERNET SITE 2008 February 29
20. 1026803 Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Stafforini DM CARDIOVASC DRUGS THER 2009 23 1 73-83
21. 1026938 New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Tsimikas S, Tsironis LD, Tselepis AD ARTERIOSCLER THROMB VASC BIOL 2008 27 10 2094-2099
22. 1026943 Lipoprotein-associated phospholipase A2: A risk marker or a risk factor?. Lerman A, McConnell JP AM J CARDIOL 2008 101 12 11F-22F
23. 1026944 Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R ARTERIOSCLER THROMB VASC BIOL 2006 26 11 2523-2529
24. 1026953 Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Wilensky RL, Shi Y, Mohler ER, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ et al NAT MED 2008 14 10 1059-1066
25. 1030006 Darapladib, a selective inhibitor of Lp-PLA2, reduces coronary atherosclerosis in diabetic, hypercholesterolemic swine. Wilensky RL, Shi Y, Zalewski A, Mohler ER, Hamamdzic D, Li JU, Pelcovitz D, Webb C, Burgett ME, Walker MC, Macphee CH CIRCULATION 2007 116 16 Abs 266
26. 1030015 The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with coronary heart disease or risk equivalent. Mohler ER, Ballantyne C, Davidson M, Hanefeld M, Ruilope L, Johnson J, Zalewski A J AM COLL CARDIOL 2008 51 10 Suppl 1 Abs 1007-1168
27. 1031282 Selective inhibition of lipoprotein-associated phospholipase A2 attenuates markers of plaque vulnerability in humans. Shi Y, Zalewski A, Macphee C, Dawson M CIRCULATION 2007 116 Suppl 16 Abs 594
28. 1032846 A study to evaluate the effect of repeat oral doses of SB-480848 on platelet function as compared to placebo in healthy subjects. Shaddinger BC, Gao L, Cai G, Wentzell LM, Johnson AG CLIN PHARMACOL THER 2006 79 2 PII-3
29. 1035026 Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Corson MA, Jones PH, Davidson MH AM J CARDIOL 2008 101 12A 41F-50F
30. 1035403 Statins and LDL-cholesterol lowering: An overview. Stroes E CURR MED RES OPIN 2005 21 S09-S16
31. 1035548 Phospholipase A2 biochemistry. Burke JE, Dennis EA CARDIOVASC DRUGS THER 2009 23 1 49-59
32. 1035576 C-reactive protein and interleukin-6 in vascular disease: Culprits or passive bystanders? Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P J HYPERTENS 2003 21 10 1787-1803
33. 1037780 Cardiovascular diseases. Fact sheet No 317. World Health Organization INTERNET SITE 2007 February 28